Bristol-Myers Squibb’s Big Bet on ImClone
ImClone’s pipeline of cancer-fighting compounds could fill a big gap in Bristol’s portfolio after key drugs go off patent, say analysts
Original post by Admin
Leave a Reply
You must be logged in to post a comment.